-VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus-
"With a deep history in developing new medicines for viral infections
and diseases, Janssen is well-positioned to advance the global
development of VX-787 for the treatment of influenza," said
About the Collaboration
Under the terms of the collaboration, Janssen will have full global
development and commercialization rights to VX-787. Vertex will receive
VX-787 is an investigational medicine that is designed to directly inhibit replication of influenza A, including recent H1 (pandemic) and H5 (avian) influenza strains, based on in-vitro data. VX-787's mechanism represents a new class of potential medicines for the treatment of influenza, distinct from neuraminidase inhibitors, the current standard of care for the treatment of influenza. VX-787 is intended to provide a rapid onset of action and an expanded treatment window.
In a Phase 2a influenza challenge study, statistically significant
improvements in viral and clinical measurements of influenza infection
were observed after treatment with VX-787. The study met its primary
endpoint and showed a statistically significant decrease in the amount
of virus in nasal secretions (viral shedding) over the seven-day study
period. In addition, at the highest dosing regimen evaluated in the
study, there was a statistically significant reduction in the severity
and duration of influenza-like symptoms. In this study, VX-787 was
generally well-tolerated, with no adverse events leading to
discontinuation. Those who took part in the study volunteered to be
experimentally exposed to an attenuated form of live H3N2 influenza A
virus. H3N2 is a common type of influenza virus and was the most common
type observed in the 2012/2013 influenza season in
VX-787 was discovered by Vertex scientists.
Often called "the flu," seasonal influenza is caused by influenza
viruses, which infect the respiratory tract.1 The flu can
result in seasonal epidemics2 and can produce severe disease
and high mortality in certain populations, such as the elderly.3
Each year, on average 5 to 20 percent of the U.S. population gets the flu4
resulting in more than 200,000 flu-related hospitalizations and 36,000
deaths.5 The overall national economic burden of
influenza-attributable illness for adults is
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in
Vertex's press releases are available at www.vrtx.com.
Special Note Regarding Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Leiden's statements in the second paragraph of the press release and statements regarding (i) the up-front payment, which is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and (ii) potential development and commercial milestone and royalty payments. While Vertex believes the forward-looking statements contained in this press release are accurate, those statements are subject to risks and uncertainties that could cause actual outcomes to vary materially from the outcomes referenced in the forward-looking statements. These risks and uncertainties include, among other things, the risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
News Provided by Acquire Media